ArticleJournal of diabetes research2014
Insulin detemir causes lesser weight gain in comparison to insulin glargine: role on hypothalamic NPY and galanin.
Article in Journal of diabetes research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study.Journal of diabetes investigation · 2021Trial
- Trends in baseline HbA1c and body-mass index in randomised trials of people with type 1 diabetes from 1993 to 2025: an IMI2 SOPHIA systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Human amniotic fluid stem cell therapy can help regain bladder function in type 2 diabetic rats.World journal of stem cells · 2022Article
- Neuropeptidergic Control of Feeding: Focus on the Galanin Family of Peptides.International journal of molecular sciences · 2021Review
- Comparison of Insulin Glargine and Detemir Effects on Hormones of Appetite and Metabolic Control in Patients with Type 1 Diabetes: A Randomized Clinical Trial.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Galanin enhances systemic glucose metabolism through enteric Nitric Oxide Synthase-expressed neurons.Molecular metabolism · 2018Article
- Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial.Nutrition & metabolism · 2018Article
- Central effects of insulin detemir on feeding, body weight, and metabolism in rats.American journal of physiology. Endocrinology and metabolism · 2017Article
- The influence of dopamine-beta-hydroxylase and catecholDiabetology & metabolic syndrome · 2017Article
- Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?Diabetes, obesity & metabolism · 2015Review
- Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes.Journal of diabetes and metabolic disorders · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCompared with other insulin analogues, insulin detemir induces less weight gain. This study investigated whether this effect was achieved by influencing the hypothalamic appetite regulators neuropeptide Y (NPY) and galanin (GAL).
methodsType 2 diabetic rat models were established with a high-fat diet and intraperitoneal injection of STZ. All rats were divided into NC, DM, DM+DE and DM+GLA groups. Glycemic levels of all study groups were checked at study onset and after 4 weeks of insulin treatment. Food intake and body weight were monitored during treatment. After 4 weeks, the hypothalamus of rats was examined for NPY and GAL mRNA and protein expression.
resultsAfter 4 weeks of treatment, compared with the DM+GLA group, the DM+DE group exhibited less food intake (P < 0.05) and less weight gain (P < 0.05), but showed similar glycemic control. The expression of hypothalamic NPY and GAL at both mRNA and protein level were significantly lower (P < 0.05) in the DM+DE group.
conclusionInsulin detemir decreased food intake in type 2 diabetic rats, which led to reduced weight gain when compared to insulin glargine treatment. This effect is likely due to downregulation of hypothalamic NPY and GAL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.